Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biomarkers of PARP inhibitor sensitivity.

Literature DB >> 21301956

Biomarkers of PARP inhibitor sensitivity.

Nicholas C Turner¹, Alan Ashworth.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2011 PMID： 21301956 DOI： 10.1007/s10549-011-1375-8

Source DB: PubMed Journal: Breast Cancer Res Treat ISSN： 0167-6806 Impact factor: 4.872

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.

Authors: Loren S Michel; Samantha Dyroff; Frank J Brooks; Katherine J Spayd; Sora Lim; Jacquelyn T Engle; Sharon Phillips; Benjamin Tan; Andrea Wang-Gillam; Christopher Bognar; Wenhua Chu; Dong Zhou; Robert H Mach; Richard Laforest; Delphine L Chen
Journal: Radiology Date: 2016-11-14 Impact factor: 11.105

2. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.

Authors: Lebaron C Agostini; Grace A McCarthy; Aditi Jain; Saswati N Chand; AnnJosette Ramirez; Avinoam Nevler; Joseph Cozzitorto; Christopher W Schultz; Cinthya Yabar Lowder; Kate M Smith; Ian D Waddell; Maria Raitses-Gurevich; Chani Stossel; Yulia Glick Gorman; Dikla Atias; Charles J Yeo; Jordan M Winter; Kenneth P Olive; Talia Golan; Michael J Pishvaian; Donald Ogilvie; Dominic I James; Allan M Jordan; Jonathan R Brody
Journal: Cancer Res Date: 2019-07-04 Impact factor: 12.701

3. Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine.

Authors: Rosa Murria; Sarai Palanca; Inmaculada de Juan; Cristina Alenda; Cecilia Egoavil; Francisco J Seguí; Zaida García-Casado; María J Juan; Ana B Sánchez; Ángel Segura; Ana Santaballa; Isabel Chirivella; Marta Llop; Gema Pérez; Eva Barragán; Dolores Salas; Pascual Bolufer
Journal: Am J Cancer Res Date: 2015-06-15 Impact factor: 6.166

4. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

Authors: Denise M Wolf; Christina Yau; Ashish Sanil; Annuska Glas; Emanuel Petricoin; Julia Wulfkuhle; Tesa M Severson; Sabine Linn; Lamorna Brown-Swigart; Gillian Hirst; Meredith Buxton; Angela DeMichele; Nola Hylton; Fraser Symmans; Doug Yee; Melissa Paoloni; Laura Esserman; Don Berry; Hope Rugo; Olufunmilayo Olopade; Laura van 't Veer
Journal: NPJ Breast Cancer Date: 2017-08-25

5. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.

Authors: Shiv K Gupta; Emily J Smith; Ann C Mladek; Shulan Tian; Paul A Decker; Sani H Kizilbash; Gaspar J Kitange; Jann N Sarkaria
Journal: Front Oncol Date: 2019-01-22 Impact factor: 6.244

6. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Authors: Anneleen Daemen; Denise M Wolf; James E Korkola; Obi L Griffith; Jessica R Frankum; Rachel Brough; Lakshmi R Jakkula; Nicholas J Wang; Rachael Natrajan; Jorge S Reis-Filho; Christopher J Lord; Alan Ashworth; Paul T Spellman; Joe W Gray; Laura J van't Veer
Journal: Breast Cancer Res Treat Date: 2012-08-09 Impact factor: 4.872

10. Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Authors: Maryam Zanjirband; Nicola Curtin; Richard J Edmondson; John Lunec
Journal: Oncotarget Date: 2017-07-15